The International Testing Agency (ITA), appointed to independently handle the results management and intelligence & investigations of anti-doping rule violations (ADRVs) for IRONMAN, reports that Swiss triathlete Imogen Simmonds has agreed to a finding of No Fault after testing positive for SARMS LGD-4033 (ligandrol) metabolite Dihydroxy-LGD-4033.

As previously announced, the athlete provided a sample under the Testing Authority and Results Management Authority of IRONMAN during an unannouced out-of-competiton doping control performed on 8 December 2024. This doping control yielded an adverse analytical finding¹ (AAF) for ligandrol.

Ligandrol is prohibited under the WADA Prohibited List as S1.2 Other Anabolic Agents. Ligandrol is banned at all times (in- and out-of-competition) and is considered a non-specified substance. Ligandrol is a selective androgen receptor modulator which promotes muscle growth and enhances physical performance.

Over the course of the results management proceedings, the athlete was able to establish that the presence of ligandrol in her sample was due to inadvertent contamination through intimate contact with her partner who was taking supplements containing the prohibited substance without her knowledge.

The athlete was also able to establish that she bore No Fault or Negligence² for the ADRV and, therefore, no period of ineligibility is imposed³ and the athlete is free to compete effective immediately. As the sample was collected out-of-competition, there are no competitive results to disqualify.

The athlete accepted the finding of the ADRV⁴, and the matter is considered as concluded from the perspective of IRONMAN and the ITA. Pursuant to the public disclosure requirement of the World Anti-Doping Code and the IRONMAN anti-doping rules, the case must be publicly reported.

The decision may be challenged before the appeal division of the Court of Arbitration of Sport by the parties with a right of appeal, in accordance with Article 13.2.3 of the IRONMAN anti-doping rules.

The ITA will not comment further on this case.